Last checked at 8 Mar 2016 11:10
RNS : FOR IMMEDIATE RELEASE | 8 MARCH 2016
|
TR1 NOTIFICATION OF MAJOR INTEREST BY AVIVA
ImmuPharma PLC (LSE:IMM), ("ImmuPharma" or the "Company"), the specialist drug discovery and development company, confirms that it has received a TR-1 by Aviva plc and its subsidiaries ("Aviva") confirming its increased holding in ImmuPharma to 11,332,848 Ordinary Shares.
This increased holding follows on from Aviva's participation in ImmuPharma's recent £8.4 million fundraising in February the issue and allotment of, in aggregate, 33,158,756 new ordinary shares of 10 pence each in the Company. ImmuPharma now has a total of 121,781,219 Ordinary Shares in issue, which takes Aviva's current position in the Company to 9.31%.
Full disclosure of the TR1 is shown below:
TR-1: NOTIFICATION OF MAJOR INTEREST IN SHARESi |
1. Identity of the issuer or the underlying issuerof existing shares to which voting rights areattached: ii | Immupharma plc | ||||
2 Reason for the notification (please tick the appropriate box or boxes): | |||||
An acquisition or disposal of voting rights | |||||
An acquisition or disposal of qualifying financial instruments which may result in the acquisition of shares already issued to which voting rights are attached | |||||
An acquisition or disposal of instruments with similar economic effect to qualifying financial instruments | |||||
An event changing the breakdown of voting rights | |||||
Other (please specify): |
CHANGE TO THE NUMBER OF VOTING RIGHTS IN ISSUE, FOLLOWING THE RECENT ISSUE OF EQUITY.
| √ | |||
3. Full name of person(s) subject to thenotification obligation: iii | Aviva plc & its subsidiaries | ||||
4. Full name of shareholder(s) (if different from 3.):iv | Registered Holder:
BNY Norwich Union Nominees Limited 628,858* Chase (GA Group) Nominees Limited 9,103,449* *denotes direct interest Chase (GA Group) Nominees Limited 696,778
Chase Nominees Limited 275,292
Vidacos Nominees Limited 528,471
| ||||
5. Date of the transaction and date onwhich the threshold is crossed orreached: v | 04 March 2016 | ||||
6. Date on which issuer notified: | 07 March 2016 | ||||
7. Threshold(s) that is/are crossed orreached: vi, vii | 8% to 7% Change at Direct Interest Level (Box 8A) | ||||
8. Notified details: | ||||||||||
A: Voting rights attached to shares viii, ix | ||||||||||
Class/type ofshares if possible usingthe ISIN CODE | Situation previousto the triggeringtransaction | Resulting situation after the triggering transaction | ||||||||
NumberofShares | NumberofVotingRights | Numberof shares | Number of votingrights | % of voting rights x | ||||||
Direct | Direct xi | Indirect xii | Direct | Indirect | ||||||
Ordinary Shares
GB0033711010 | 8,140,848 | 8,140,848 | 11,232,848 | 9,732,307 | 1,500,541 | 7.99% | 1.24% | |||
| ||||||||||
B: Qualifying Financial Instruments | ||||||||||
Resulting situation after the triggering transaction | ||||||||||
Type of financialinstrument | Expirationdate xiii | Exercise/Conversion Period xiv | Number of votingrights that may beacquired if theinstrument isexercised/ converted. | % of votingrights | ||||||
RIGHT TO RECALL LOANED SHARES | N/A | N/A | 100,000 *
* Direct Interest | 0.08% | ||||||
C: Financial Instruments with similar economic effect to Qualifying Financial Instruments xv, xvi | ||||||
Resulting situation after the triggering transaction | ||||||
Type of financialinstrument | Exercise price | Expiration date xvii | Exercise/Conversion period xviii | Number of voting rights instrument refers to
| % of voting rights xix, xx
| |
Total (A+B+C) | |
Number of voting rights | Percentage of voting rights |
11,332,848 | 9.31% |
9. Chain of controlled undertakings through which the voting rights and/or thefinancial instruments are effectively held, if applicable: xxi | ||
The voting rights are managed and controlled by Aviva Investors Global Services Limited, with the following chain of controlled undertakings:-
Aviva Investors Global Services Limited: · Aviva plc (Parent Company) · Aviva Group Holdings Limited (wholly owned subsidiary of Aviva plc) · Aviva Investors Holdings Limited (wholly owned subsidiary of Aviva Group Holdings Limited) · Aviva Investors Global Services Limited (wholly owned subsidiary of Aviva Investors Holdings Limited)
| ||
Proxy Voting: | ||
10. Name of the proxy holder: | See Section 4 | |
11. Number of voting rights proxy holder will ceaseto hold: | ||
12. Date on which proxy holder will cease to holdvoting rights: | ||
13. Additional information: | Figures are based the revised total number of voting rights of 121,781,219 as per the recent Confirmation of EIS and VCT Qualifying Status and Issue of Equity announcement of 01 March 2016.
| |
14. Contact name: | Michael Dunhill, Aviva plc | |
15. Contact telephone number: | 01603 685988 | |
-Ends-
For further information please contact:
|
Notes to Editors
ImmuPharma PLC
ImmuPharma is a pharmaceutical development company listed since 2006 on AIM of the London Stock Exchange (LSE:IMM), focusing on developing novel medicines with high sales potential in specialist markets with serious unmet need. ImmuPharma is led by a commercially focused Board and management team with extensive experience.
ImmuPharma announced on 1 March 2016 the successful completion of a £8.4 million fund raise, comprising a Placing and Subscription together with confirmation of EIS and VCT qualifying status. Monies raised will principally be used to complete the pivotal Phase III trial of Lupuzor™. Following the issue of the New Ordinary Shares referred to above, ImmuPharma will have 121,781,219 ordinary shares of 10 pence each (the "Ordinary Shares") in issue.
LupuzorTM
LupuzorTM (also referred to as forigerimod, rigerimod, IPP-201101 or P140 is ImmuPharma's lead compound and a potential treatment for lupus (or Systemic Lupus Erythematosus), a chronic, potentially life-threatening auto-immune disease. LupuzorTM has a novel mechanism of action aimed at modulating the body's immune system so that it does not attack healthy cells, and avoids causing adverse side effects. It has the potential to halt the progression of the disease in a substantial proportion of patients.
LupuzorTM has been granted Fast Track status by the US FDA and approval to start Phase III under Special Protocol Assessment (SPA). This SPA was subsequently amended due to its strong safety and efficacy profile to allow for a reduced number of patients in the pivotal Phase III trial thereby reducing the projected cost and time of development considerably.
The pivotal Phase III clinical study is entitled "A 52-Week, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled Study to Evaluate the Efficacy and Safety of a 200-mcg Dose of IPP-201101 Plus Standard of Care in Patients With Systemic Lupus Erythematosus". It is a pivotal study designed to demonstrate the safety and efficacy of IPP-201101 and as a last step prior to the filing of the drug for approval with the US Food & Drug Administration ("FDA") and the European Medicines Agency ("EMA"). For more information please visit: www.ClinicalTrials.gov/lupuzor
Commercial Opportunity
There are an estimated five million people globally suffering from Lupus, with approximately 1.5 million patients in the US, Europe and Japan (Source: Lupus Foundation of America). Current 'standard of care' treatments, including steroids and immunosuppressants, can potentially have either serious side effects for patients or limited effectiveness, with over 60% of patients not adequately treated. GSK's Benlysta is the first Lupus drug approved in over 50 years and paves the path to market for Lupuzor™. Based on conservative estimates, and taking into account that Benlysta is priced currently at approximately $35,000 per patient per year, Lupuzor™ would be entering a market with the potential for multi-billion dollar sales. For more information on Lupuzor™ please visit: www.lupuzor.com